Related references
Note: Only part of the references are listed.Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: Recommendations of the prostate cancer clinical trials working group
Howard I. Scher et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Incidence and risk of hypertension with sorafenib in patients with cancer: a systematic review and meta-analysis
Shenhong Wu et al.
LANCET ONCOLOGY (2008)
Epidermal growth factor receptor (EGFR) expression in prostatic adenocarcinoma after hormonal therapy: A fluorescence in situ hybridization and immunohistochemical analysis
Rebecca A. Marks et al.
PROSTATE (2008)
A phase II study of sorafenib in patients with chemo-naive castration-resistant prostate cancer
K. N. Chi et al.
ANNALS OF ONCOLOGY (2008)
Supra-additive antitumor effect of sunitinib malate (SU11248, Sutent (R)) combined with docetaxel. A new therapeutic perspective in hormone refractory prostate cancer
O. Guerin et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2008)
Prostate-specific antigen and prostate cancer: prediction, detection and monitoring
Hans Lilja et al.
NATURE REVIEWS CANCER (2008)
A clinical phase II study with sorafenib in patients with progressive hormone-refractory prostate cancer: a study of the CESAR Central European Society for Anticancer Drug Research-EWIV
S. Steinbild et al.
BRITISH JOURNAL OF CANCER (2007)
Clinical significance of epidermal growth factor receptor protein overexpression and gene copy number gains in prostate cancer
Thorsten Schlomm et al.
CLINICAL CANCER RESEARCH (2007)
A phase II trial of gefitinib in patients with non-metastatic hormone-refractory prostate cancer
Eric J. Small et al.
BJU INTERNATIONAL (2007)
Phase I dose escalation and pharmacokinetic study of AZD2171, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinase, in patients with hormone refractory prostate cancer (HRPC)
Charles J. Ryan et al.
INVESTIGATIONAL NEW DRUGS (2007)
Randomized, placebo-controlled phase II study of vandetanib plus docetaxel in previously treated non-small-cell lung cancer
John V. Heymach et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Prostate-specific antigen and pain surrogacy analysis in metastatic hormone-refractory prostate cancer
Andrew J. Armstrong et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
A phase II trial of docetaxel and erlotinib as first-line therapy for elderly patients with androgen-independent prostate cancer
Mitchell Gross et al.
BMC CANCER (2007)
Phase I clinical study of AZD2171, an oral vascular endothelial growth factor signaling inhibitor, in patients with advanced solid tumors
Joachim Drevs et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Double-blinded randomized study of high-dose calcitriol plus docetaxel compared with placebo plus docetaxel in androgen-independent prostate cancer: A report from the ASCENT investigators
Tomasz M. Beer et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Vandetanib (ZD6474): an orally available receptor tyrosine kinase inhibitor that selectively targets pathways critical for tumor growth and angiogenesis
Roy S. Herbst et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2007)
A phase I dose-escalation study of ZD6474 in Japanese patients with solid, malignant tumors
Tomohide Tamura et al.
JOURNAL OF THORACIC ONCOLOGY (2006)
Evaluation of prostate-specific antigen declines for surrogacy in patients treated on SWOG 99-16
DP Petrylak et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2006)
Design issues of randomized phase II trials and a proposal for phase II screening trials
LV Rubinstein et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Is prostate-specific antigen a valid surrogate end point for survival in hormonally treated patients with metastatic prostate cancer?: Joint research of the European Organisation for Research and Treatment of Cancer, the Limburgs Universitair Centrum, and AstraZeneca Pharmaceuticals
L Collette et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Clinical evaluation of ZD6474, an orally active inhibitor of VEGF and EGF receptor signaling, in patients with solid, malignant tumors
SN Holden et al.
ANNALS OF ONCOLOGY (2005)
ZD6474 - a novel inhibitor of VEGFR and EGFR tyrosine kinase activity
AJ Ryan et al.
BRITISH JOURNAL OF CANCER (2005)
Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer
DP Petrylak et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer
IF Tannock et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Share Paper
